Literature DB >> 16643825

Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy.

Wessel Ganzevoort1, Annelies Rep, Johanna I P de Vries, Gouke J Bonsel, Hans Wolf.   

Abstract

OBJECTIVE: We explored the association between clinical parameters at admission and the subsequent development of major maternal complications or adverse infant outcome in women with hypertensive complications of pregnancy remote from term. STUDY
DESIGN: We drew data from a randomized trial of temporizing management in 216 patients with hemolysis, elevated liver enzymes, and low platelets syndrome; severe preeclampsia; eclampsia; or hypertension-related fetal growth restriction and gestational ages between 24 and 34 completed weeks. End points were adverse infant outcome (perinatal death, severe morbidity) and major maternal complications (major morbidity; recurrent and newly acquired hemolysis, elevated liver enzymes, and low platelets; eclampsia) after admission. End point prevalences were comparable between the treatment and control groups. The association with age, parity, ethnicity, body mass index, gestational age, estimated fetal weight, blood pressure, antihypertensive medication, pulse rate, hemoglobin concentration, admitting center, diagnosis at inclusion, chronic hypertension, and thrombophilia was explored by logistic regression analysis.
RESULTS: Adverse infant outcome was predominantly influenced by gestational age (odds ratio 0.4 per week increment). Major maternal complications were correlated to multiparity (odds ratio 0.4) and estimated fetal weight (odds ratio 0.9 per 100-g increment).
CONCLUSION: Prediction at admission of the clinical course of the disease and the development of additional maternal complications was not feasible.

Entities:  

Mesh:

Year:  2006        PMID: 16643825     DOI: 10.1016/j.ajog.2006.02.012

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  20 in total

1.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

2.  Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study.

Authors:  Piya Chaemsaithong; Roberto Romero; Adi L Tarca; Steven J Korzeniewski; Alyse G Schwartz; Jezid Miranda; Ahmed I Ahmed; Zhong Dong; Sonia S Hassan; Lami Yeo; Tinnakorn Tinnakorn
Journal:  J Matern Fetal Neonatal Med       Date:  2014-09-29

Review 3.  Angiogenic factors in preeclampsia: potential for diagnosis and treatment.

Authors:  Arvind Goel; Sarosh Rana
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-11       Impact factor: 2.894

4.  Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia.

Authors:  Giovanna Ogge; Tinnakorn Chaiworapongsa; Roberto Romero; Youssef Hussein; Juan Pedro Kusanovic; Lami Yeo; Chong Jai Kim; Sonia S Hassan
Journal:  J Perinat Med       Date:  2011-08-17       Impact factor: 1.901

5.  Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study.

Authors:  Roberto Romero; Piya Chaemsaithong; Adi L Tarca; Steven J Korzeniewski; Eli Maymon; Percy Pacora; Bogdan Panaitescu; Noppadol Chaiyasit; Zhong Dong; Offer Erez; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2017-03-01

6.  Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Josef M Cortez; Athina Pappas; Adi L Tarca; Piya Chaemsaithong; Zhong Dong; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2013-08-08

Review 7.  Angiogenic factors in diagnosis, management, and research in preeclampsia.

Authors:  Sarosh Rana; S Ananth Karumanchi; Marshall D Lindheimer
Journal:  Hypertension       Date:  2013-10-28       Impact factor: 10.190

8.  Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia.

Authors:  Sarosh Rana; Michele R Hacker; Anna Merport Modest; Saira Salahuddin; Kee-Hak Lim; Stefan Verlohren; Frank H Perschel; S Ananth Karumanchi
Journal:  Hypertension       Date:  2012-07-02       Impact factor: 10.190

9.  Risk factors for adverse maternal and perinatal outcomes in women with preeclampsia: analysis of 1396 cases.

Authors:  Xun Li; Weishe Zhang; Jianhua Lin; Huai Liu; Zujing Yang; Yincheng Teng; Si Duan; Xinxiu Lin; Yingming Xie; Yuanqiu Li; Liangqun Xie; Qiaozhen Peng; Lu Xia
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-30       Impact factor: 3.738

10.  Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.

Authors:  Sarosh Rana; Camille E Powe; Saira Salahuddin; Stefan Verlohren; Frank H Perschel; Richard J Levine; Kee-Hak Lim; Julia B Wenger; Ravi Thadhani; S Ananth Karumanchi
Journal:  Circulation       Date:  2012-01-18       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.